New hope for blood cancer patients: experimental drug aims to keep disease at bay longer
NCT ID NCT07297329
Summary
This study is testing whether adding an experimental drug called SCTC21C to a standard three-drug combination works better for controlling newly diagnosed multiple myeloma. It will involve about 292 adults with this blood cancer who are not eligible for a stem cell transplant. Researchers want to see if the four-drug combination keeps the cancer from progressing longer and helps more patients achieve a deeper state of remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Chaoyang Hospital affiliated to Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.